Circio invites to R&D and corporate update webcast on 28 May 2025

22 May 2025 07:00 CEST

· CTO Dr. Thomas B Hansen will present a summary of recent in vivo results
validating circVec performance in novel AAV and DNA formats for gene and cell
therapy
· CEO Dr. Erik D Wiklund will provide a corporate and business development
update, incl.  information related to the upcoming annual general meeting

Oslo, Norway 22 May 2025 - Circio Holding ASA (OSE: CRNA), a biotechnology
company developing powerful circular RNA technology for next generation nucleic
acid medicine, invites to a live webcast at 10:00am CEST on Wednesday 28 May
2025.

In the webcast, CTO Dr. Thomas B Hansen will present Circio´s latest circVec
platform in vivo results. Recent findings include validation of the circVec
platform using novel AAV and DNA vector formats, and demonstrate enhanced and
distinct tissue expression profiles vs. equivalent conventional mRNA-based
vectors. The results highlight potential applications for circVec in tissue
targeted gene therapy and in vivo cell therapy; a field that is advancing
rapidly and gaining strong momentum in the industry.

CEO Dr. Erik D Wiklund will provide a corporate update including business
development activities and background and practical information relating to
proposals for shareholder approval at the annual general meeting to be held on 5
June 2025.

Presenters:
CEO Dr. Erik Digman Wiklund
CTO Dr. Thomas Birkballe Hansen

Time: 10:00 CEST on 28 May 2025

Click here to access Teams
webcast (https://teams.microsoft.com/meet/3919530790393?p=D2tS9HOrDxAFf5WhLj)
Meeting ID: 391 953 079 039 3
Passcode: PB2gk7wt

Questions can be submitted in advance by email to Erik D Wiklund:
erik.wiklund@circio.com or directly in the live webcast

A recording of the webcast will be made available on the Circio
webpage (http://www.circio.com/)

More information:
Access the news on Oslo Bors NewsWeb site